Izabrani naučni radovi iz časopisa The Lancet Diabetes & Endocrinology:
- Rubino, Francesco, et al. “Definition and Diagnostic Criteria of Clinical Obesity.” The Lancet Diabetes & Endocrinology, vol. 13, no. 3, Mar. 2025, https://linkinghub.elsevier.com/retrieve/pii/S2213-8587(24)00316-4
- Fassnacht M, Puglisi S, Kimpel O, Terzolo M. Adrenocortical carcinoma: a practical guide for clinicians. The Lancet Diabetes & Endocrinology. 2025;13(5):438-452. doi:1016/S2213-8587(24)00378-4
- Vazquez Arreola, Elsa, et al. “Prediabetes Remission and Cardiovascular Morbidity and Mortality: Post-Hoc Analyses from the Diabetes Prevention Program Outcome Study and the DaQing Diabetes Prevention Outcome Study.” The Lancet Diabetes & Endocrinology, 12 Dec. 2025, https://doi.org/10.1016/S2213-8587(25)00295-5.
- Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology. 2025;13(8):674-684. doi:1016/S2213-8587(25)00092-0
Nove smjernice Američke asocijacije za dijabetes za 2026.
- American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj M, McCoy RG, et al. Summary of Revisions: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Supplement_1):S6-S12. doi:2337/dc26-SREV
Nove smjernice Američke tiroidne asocijacije za liječenje diferentovanog karcinoma štitaste žlijezde.
- Ringel MD, Sosa JA, Baloch Z, et al. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer. Thyroid®. 2025;35(8):841-985. doi:1177/10507256251363120
Nove smjernice Evropske tiroidne asocijacije za monoterapiju levotiroksinom.
- Centanni M, Duntas L, Feldt-Rasmussen U, et al. ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism. European Thyroid Journal. 2025;14(4):e250123. doi: 1530/ETJ-25-0123
Nove smjernice Endokrinog društva za dijagnostiku i liječenje primarnog aldosteronizma.
- Correction to: “Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.” The Journal of Clinical Endocrinology & Metabolism. 2025;110(11):e3933-e3934. doi:1210/clinem/dgaf472
Izabrane publikacije sa ENS@T vebsajta
- Nowak E, Viëtor CL, Feelders RA, et al. Effect of surgical versus conservative management on cardiovascular outcomes in patients with bilateral adrenal tumours and cortisol excess: an international, retrospective cohort study. The Lancet Diabetes & Endocrinology. Published online January 2026:S221385872500302X. doi:1016/S2213-8587(25)00302-X
- Spyroglou A, Konstantakou P, Minnetti M, Altieri B, Nowak E, Papalexis P, Angelousi A, Vasiliadi D, Kimpel O, Macut D, Tucci L, Donnarumma F, Di Dalmazi G, Papaioannou T, Isidori A, Reincke M, Konstadoulakis M, Mastorakos G, Kaltsas G, Alexandraki KI.Metabolic phenotype in non-aldosterone producing adrenal adenomas with co-existent polycystic ovary syndrome: a joint Ens@t project.S Endocrine. 2025 Jul 30. doi: 10.1007/s12020-025-04369-7.
- Riedmeier M, Agarwal S, Antonini SRR, Ekinci S, Fassnacht M, Figueiredo BC, Härtel C, Meena JP, Marks SD, Munarin J, Puglisi S, Tuli G, Yalcin B, Schlegel PG, Wiegering A, Wiegering V. Evaluation of prognostic factors in advanced pediatric ACC. Endocr Relat Cancer. 2025 Apr 2;32(5):e240135. doi: 10.1530/ERC-24-0135.
- Catalano R, Nozza E, Altieri B, Esposito E, Croci GA, Barbieri AM, Treppiedi D, Di Bari S, Kimpel O, Detomas M, Tamburello M, Schauer MP, Herterich S, Angelousi A, Luconi M, Canu L, Nesi G, Hantel C, Sigala S, Landwehr LS, Di Dalmazi G, Cassinotti E, Baldari L, Palmieri S, Mangone A, Ferrante E, Ronchi CL, Mantovani G, Peverelli E. Emerging role of IGF1R and IR expression and localisation in adrenocortical carcinomas. Cell Commun Signal. 2025 Mar 4;23(1):119. doi: 1186/s12964-025-02115-0. PMID: 40038716; PMCID: PMC11877998.
